Lori Macomber
Director of Finance/CFO bij LEGEND BIOTECH CORPORATION
Vermogen: 426 621 $ op 31-03-2024
Profiel
Lori Macomber is currently the Chief Financial Officer at Legend Biotech Corp.
She previously worked as the Business Unit Controller at AMETEK, Inc. from 2018 to 2019, the Assistant VP-Finance Site Leader at Eli Lilly & Co. from 2010 to 2017, and the Controller & Chief Financial Officer-US Region at Cello Health Ltd.
from 2017 to 2018.
Ms. Macomber obtained her undergraduate degree from The Pennsylvania State University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LEGEND BIOTECH CORP.
0.01% | 31-12-2022 | 15 212 ( 0.01% ) | 426 621 $ | 31-03-2024 |
Actieve functies van Lori Macomber
| Bedrijven | Functie | Begin |
|---|---|---|
| LEGEND BIOTECH CORPORATION | Director of Finance/CFO | 09-05-2022 |
Eerdere bekende functies van Lori Macomber
| Bedrijven | Functie | Einde |
|---|---|---|
| AMETEK, INC. | Corporate Officer/Principal | 01-09-2019 |
| CELLO HEALTH PLC | Comptroller/Controller/Auditor | 01-02-2018 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01-04-2017 |
Opleiding van Lori Macomber
| The Pennsylvania State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| AMETEK, INC. | Producer Manufacturing |
| ELI LILLY AND COMPANY | Health Technology |
| LEGEND BIOTECH CORPORATION | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Cello Health Ltd.
 Cello Health Ltd. Miscellaneous Commercial ServicesCommercial Services Cello Health Plc provides strategic marketing services. It operates through two segments: Cello Health and Cello signal. The Cello Health segment provides market research, consulting, and communications services principally to its pharmaceutical and healthcare clients and Signal segment provides market research and direct communications services principally to its consumer facing clients. The company was founded by Mark Coleridge Scott and Kevin Barrie Steeds on May 5, 2004 and is headquartered in London, the United Kingdom. | Commercial Services |
